Safety and Efficacy of Oral Progesterone for Menopausal Symptoms

Efficacy and Safety Considerations

For women with an intact uterus who are taking estrogen therapy, progesterone is mandatory to prevent endometrial hyperplasia and cancer, reducing the risk by approximately 90% 1

The U.S. Preventive Services Task Force recommends against the routine use of hormone therapy for primary prevention of chronic conditions 2
Combined estrogen-progestin therapy is associated with increased risks of stroke 6, deep vein thrombosis and pulmonary embolism 6, invasive breast cancer 6, gallbladder disease 7, and urinary incontinence 7
For women with an intact uterus who are taking estrogen for menopausal symptoms, progesterone must be added to prevent endometrial hyperplasia 8, 1
Progesterone therapy should be individualized based on symptom severity, risk factors, and patient preferences 1
Hormone therapy is contraindicated in women with a history of breast cancer 1, coronary heart disease 1, previous venous thromboembolic events or stroke 1, active liver disease 1, or antiphospholipid syndrome 1

For women with early or premature menopause without contraindications, hormone therapy (which may include progesterone) is recommended at least until the average age of natural menopause 8
The benefit-risk profile is most favorable for women under 60 years of age or within 10 years of menopause onset 1
For women with surgical menopause due to hysterectomy, estrogen alone without progesterone is appropriate 8

Using hormone therapy solely for prevention of chronic conditions rather than symptom management 5
Failing to distinguish between different hormone therapy regimens and routes of administration, which can have varying risk profiles 1
Continuing hormone therapy longer than necessary for symptom relief 5, 1